Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States

被引:37
作者
Bhavnani, SM [1 ]
Hammel, JP
Jones, RN
Ambrose, PG
机构
[1] Ordway Res Inst, Inst Clin Pharmacodynam, Albany, NY 12208 USA
[2] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14221 USA
[3] JMI Labs, JONES Grp, N Liberty, IA 52317 USA
[4] Tufts Univ, Sch Med, Boston, MA 02111 USA
[5] Cognigen Corp, Buffalo, NY 14221 USA
关键词
lexofloxacin; Streptococcus pneumoniae; fluoroquinolone resistance; United States;
D O I
10.1016/j.diagmicrobio.2004.08.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Increasing reports of fluoroquinolone-non-susceptible Streptococcus pneunioniae are of clinical concern. We examined the relationship between outpatient fluoroquinolone use and susceptibility of community -acquired S. pneumoniae isolates. Using multivariable general linear modeling, US SENTRY Antimicrobial Surveillance Program and Intercontinental Medical Statistics data (1997-2002) were analyzed to determine the influence of selected patient-, institution-, and geographic region-specific factors, including local fluoroquinolone usage, on the minimum inhibitory concentration (MIC) of levofloxacin against S. pneunioniae. Levofloxacin MIC50, MIC90, and MIC range (it = 3 84 from 26 hospitals) were 1, 1, and less than or equal to 0.5 to > 4 mug/mL, respectively. (.)Variables associated with changes in geometric mean MIC included geographical region (P < 0.0001), medical service (P = 0.0002), study year (P = 0.0006), primary diagnosis group (P = 0.02), and 2 interactions (duration of hospital stay before isolate collection by bed capacity, P = 0.06, and levofloxacin use by geographical region, P = 0.08; P < 0.001 when study year was removed from the model). MIC increased with levofloxacin use across all geographical regions, with increases of 54% and 126% in the southwest and west, respectively. In contrast to other fluoroquinolones, increased levofloxacin use, along with other variables, was associated with decreased pneumococcal susceptibility. Given the US environment of increasing pneumococcal resistance, these data may be useful in better understanding factors related to emergence of fluoroquinolone resistance. (C) 2005 Published by Elsevier Inc.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 39 条
[21]   Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia [J].
Kays, MB ;
Smith, DW ;
Wack, MF ;
Denys, GA .
PHARMACOTHERAPY, 2002, 22 (03) :395-399
[22]   Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection [J].
Lacy, MK ;
Lu, W ;
Xu, XW ;
Tessier, PR ;
Nicolau, DP ;
Quintiliani, R ;
Nightingale, CH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :672-677
[23]  
Lim S, 2003, EMERG INFECT DIS, V9, P833
[24]   Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae [J].
Lister, PD ;
Sanders, CC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :79-86
[25]   Pharmaco dynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model:: Impact of area under the curve/MIC ratios on eradication [J].
Lister, PD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :69-74
[26]   Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae [J].
Lister, PD ;
Sanders, CC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (06) :811-818
[27]   Guidelines for community-acquired pneumonia: A tale of 2 countries [J].
Mandell, LA .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :422-425
[28]   Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults [J].
Mandell, LA ;
Bartlett, JG ;
Dowell, SF ;
File, TM ;
Musher, DM ;
Whitney, C .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (11) :1405-1432
[29]  
MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033
[30]  
National Committee for Clinical Laboratory Standards - NCCLS, 2004, M100S14 NCCLS